Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Genitourinary 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Carcinoma In Situ 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 70Letrozole 63Cyclophosphamide 61Paclitaxel 60Specimen Handling 54pertuzumab 52Docetaxel 50abemaciclib 46ribociclib 45Anastrozole 36Magnetic Resonance Spectroscopy 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Blood Specimen Collection 33exemestane 32Tamoxifen 32Biopsy 32sacituzumab govitecan 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Drug Therapy 28Surveys and Questionnaires 27Injections 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Bone Density × Breast × Clear all
NCT07044310 2025-07-29

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Mayo Clinic

Phase 2 Recruiting
38 enrolled
Breast

Breast Carcinoma In Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡